e. To participate in the conference call, interested parties should dial 612-332-0630. In addition, a live webcast of the call can be accessed by visiting the Investor Relations page under the Conferences & Webcasts link of the Kensey Nash website at www.kenseynash.com
and clicking on Webcast. The teleconference call will also be available for replay starting Wednesday, January 28, 2009 at 11:00 a.m. Eastern Time through Wednesday, February 4, 2009 at 11:59 p.m. Eastern Time by dialing 1-800-475-6701 with an access code of 981228.
About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company has also developed and commercialized a series of innovative endovascular products that were sold to Spectranetics Corporation in May of 2008. In conjunction with the sale transaction, the Company will continue to manufacture and develop these products for Spectranetics for a period of time. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.
Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities, including the financial forecasts for the third quarter of fiscal 2009 and the full year fiscal 2009. The Com
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related biology technology :1
|SOURCE Kensey Nash Corporation|
Copyright©2009 PR Newswire.
All rights reserved
. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results2
. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference3
. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology4
. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference5
. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference6
. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference7
. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference8
. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers9
. GEN Reports on Growing Reliance on Microfluidics Technology10
. Novozymes Reports Strong 2008 Results11
. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System